

# RECEIVED CENTRAL FAX CENTER

401 Castro Street Mountain View, CA 94041-2007 T 650.625.8100 F 650.625.8110

www.sughrue.com

NOV 2 9 2005

**FAX** 

Date

November 29, 2005

To

Centralized Delivery

Of

PTO Group Art Unit 1649

Fax

571-273-8300

From

Rosemarie L. Celli

Our Ref. No.

CA1299

Application No.

10/828,548

Conf. No.

3885

Inventor

Dale B. SCHENK

**Pages** 

(including cover sheet)

Please call attention to problems with this transmission by return fax or telephone. Thank you.

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US.

#### This fax filling includes:

- This cover sheet (1 page)
- 2. Response to Restriction Requirement. (27 pages)

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office to fax number 571-273-8300, on the date below.

Nov. 29, 2005

Date

Rosemarie L. Celli, Rcg. No. 42,397

# RECEIVED CENTRAL FAX CENTER

## NOV 2 9 2005

### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: CA1299

Dale B, SCHENK

Appln. No.: 10/828,548

Group Art Unit: 1649

Confirmation No.: 3885

Examiner: Kolker, Daniel E.

Filed: April 19, 2004

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office to fax number 571-273-8300, on the

Rosemarie L. Celli, Reg. No. 42,393

### RESPONSE TO RESTRICTION REQUIREMENT

PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Sir:

For:

This paper is submitted in response to the Restriction Requirement mailed September 29, 2005. Please enter the following amendments and remarks.

### TABLE OF CONTENTS

33827~1